This website uses cookies to improve your experience. Learn more about cookies and how to manage them.

Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF‐1 suppression to octreotide LAR in healthy volunteers

Article date: September 2015

By: Fredrik Tiberg, John Roberts, Camilla Cervin, Markus Johnsson, Severine Sarp, Anadya Prakash Tripathi, Margareta Linden, in Volume 80, Issue 3, pages 460-472


The aim was to assess the pharmacokinetics, pharmacodynamics, safety and tolerability of octreotide subcutaneous (s.c.) depot, a novel octreotide formulation.


This was a phase I, randomized, open label study. After a single dose of octreotide immediate release (IR) 200 µg, subjects were randomized to one of eight groups to receive three monthly injections of octreotide s.c. depot A 10, 20 or 30 mg, B 30 mg, C 10, 20 or 30 mg or long acting octreotide (octreotide LAR) 30 mg.


One hundred and twenty‐two subjects were randomized. For all depot variants, onset of octreotide release was rapid and sustained for up to 4 weeks. The relative octreotide bioavailability of depot variants vs. octreotide IR ranged from 0.68 (90% confidence interval [CI] 0.61, 0.76) to 0.91 (90% CI 0.81, 1.02) and, vs. octreotide LAR, was approximately four‐ to five‐fold greater: 3.97 (90% CI 3.35, 4.71) to 5.27 ng ml–1 h (90% CI 4.43, 6.27). All depot variants showed relatively rapid initial reductions of insulin‐like growth factor 1 (IGF‐1) compared with octreotide LAR. A trend of octreotide dose dependence was also indicated from the plasma concentrations and suppression of IGF‐1. Maximum inhibition of IGF‐1 at steady‐state was highest for depot B and C. All depot treatments were well tolerated. The most frequent adverse events were gastrointestinal related.


Octreotide s.c. depot provides greater octreotide bioavailability with a more rapid onset and stronger suppression of IGF‐1 than octreotide LAR in healthy volunteers.

DOI: 10.1111/bcp.12698

View this article